MIRA Pharmaceuticals
MIRA
15 hedge funds and large institutions have $1.08M invested in MIRA Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 3 closing their positions.
138% more capital invested
Capital invested by funds: $454K → $1.08M (+$625K)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
36% more funds holding
Funds holding: 11 → 15 (+4)
0.8% more ownership
Funds ownership: 4.82% → 5.62% (+0.8%)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$185K |
| 2 |
LPL Financial
San Diego,
California
|
+$79.7K |
| 3 |
SEM
Suncoast Equity Management
Tampa,
Florida
|
+$79.7K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$66.8K |
| 5 |
Millennium Management
New York
|
+$64.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$138K |
| 2 |
CSI
Cross Staff Investments
Pittsford,
New York
|
-$27.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$18.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$16.1K |
| 5 |
PWM
Praetorian Wealth Management
Carmel,
California
|
-$15.9K |
MIRA Hedge Fund Activity: Q3 2024 in Review
15 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q3 2024, worth a combined $1.08M — up 138% from $454K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MIRA positions and 3 closed out — a net gain of 4 holders — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $185K. The largest seller was Avantax Planning Partners, cutting an estimated $138K.
- 15 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q3 2024, up from 11 in Q2 2024.
- Funds reported $1.08M of MIRA Pharmaceuticals stock for Q3 2024, up 138% quarter-over-quarter.
- 7 funds opened new MIRA Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of +4 holders.
- The largest MIRA Pharmaceuticals buyer in Q3 2024 was Geode Capital Management, an estimated $185K added.
- The largest MIRA Pharmaceuticals seller in Q3 2024 was Avantax Planning Partners, an estimated $138K sold.
Based on aggregated 13F filings for Q3 2024.